907 results on '"Krämer, Alwin"'
Search Results
152. Structure meets function—Centrosomes, genome maintenance and the DNA damage response
153. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
154. CEBPAmutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome
155. RNA-Based Detection of Gene Fusions in Formalin-Fixed and Paraffin-Embedded Solid Cancer Samples
156. Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) – Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial
157. EZH2 mutations and impact on clinical outcome: an analysis in 1,604 patients with newly diagnosed acute myeloid leukemia
158. Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?
159. Comparative genetic profiling aids diagnosis and clinical decision making in challenging cases of CUP syndrome
160. Micronucleus formation in human cancer cells is biased by chromosome size
161. Integrated Clinico-Molecular Characterization Identifies RAS Activation and CDKN2A Deletion As Independent Adverse Prognostic Factors in Cancer of Unknown Primary
162. Hematological Malignancies in Adults With a Family Predisposition
163. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
164. EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia
165. PPM1D Mutations Are Rare in De Novo and Therapy-Related Acute Myeloid Leukemia
166. A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia
167. JAM-C Expression as a Biomarker to Predict Outcome of Patients with Acute Myeloid Leukemia—Letter
168. Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma
169. SMC3 protein levels impact on karyotype and outcome in acute myeloid leukemia
170. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design.
171. Impact of PTPN11mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia
172. Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial
173. Aneuploidy Precedes and Segregates with Chemical Carcinogenesis
174. Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial
175. CD7 is expressed on a subset of normal CD34-positive myeloid precursors
176. Phase I dose‐escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia
177. Integrated Histogenetic Analysis Reveals BAP1 -Mutated Epithelioid Mesothelioma in a Patient With Cancer of Unknown Primary
178. Genomic profiling of carcinomas of unknown primary (CUP) to support clinical decisions.
179. Diagnosis and management of metastatic neoplasms with unknown primary
180. The Addition of Sorafenib to Standard AML Treatment Results in a Substantial Reduction in Relapse Risk and Improved Survival. Updated Results from Long-Term Follow-up of the Randomized-Controlled Soraml Trial
181. Cep164-null cells generated by genome editing show a ciliation defect with intact dna repair capacity
182. Asymmetric Centriole Numbers at Spindle Poles Cause Chromosome Missegregation in Cancer
183. Prognostisch günstige Subgruppen bei Krebs mit unklarem Primarius
184. IDH-Inhibitoren
185. Synthesis and formulation studies of griseofulvin analogues with improved solubility and metabolic stability
186. Systemtherapie prognostisch ungünstiger CUP-Syndrome
187. Marker chromosomes can arise from chromothripsis and predict adverse prognosis in acute myeloid leukemia
188. Marker Chromosomes Can Arise from Chromothripsis and Predict Adverse Prognosis in Acute Myeloid Leukemia
189. Comparison of Treatment Strategies in Patients over 60 Years with AML: Final Analysis of a Prospective Randomized German AML Intergroup Study
190. Allogeneic Stem Cell Transplantation Improves Survival in Patients with FLT3-ITD-Negative and NPM1-Wild Type Intermediate Risk (ELN) Acute Myeloid Leukemia
191. Clinical Impact of KMT2C and SPRY4 Expression Levels in Intensively Treated Younger Adult Acute Myeloid Leukemia Patients
192. Expanded Phenotypic and Genetic Heterogeneity in the Clinical Spectrum of FPD-AML: Lymphoid Malignancies and Skin Disorders Are Common Features in Carriers of Germline RUNX1 Mutations
193. Pharmacological Inhibition of Centrosome Clustering by Slingshot-Mediated Cofilin Activation and Actin Cortex Destabilization
194. The clinical mutatome of core binding factor leukemia
195. TP53deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia
196. A phase I trial investigating the Aurora B kinase inhibitor BI 811283 in combination with cytarabine in patients with acute myeloid leukaemia.
197. Safety and efficacy of vismodegib in relapsed/refractory acute myeloid leukaemia: results of a phase Ib trial.
198. Phase I dose‐escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia.
199. Cohesin Subunit SMC3 Levels Impact on Karyotype and Outcome in Acute Myeloid Leukemia
200. Abstract 2645: BAY 1436032: A highly selective, potent and orally available inhibitor of mutant forms of IDH1
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.